Comparison · NCT02850016-2f45fca2
Group A vs Group B: Plasma HIV-1 RNA
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: Plasma HIV-1 RNA. Trial comparisons, record NCT02850016-2f45fca2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02850016-2f45fca2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.364 | 0.152 | 0.646 | wilson | |
| Risk in group 2 | 0.444 | 0.189 | 0.733 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0808 | -0.439 | 0.3 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.818 | 0.281 | 2.39 | log | |
| Odds ratio, group 1 over group 2 | 0.714 | 0.118 | 4.32 | log | |
| Number needed to treat, for one fewer participant with the outcome on Group A than on Group B | 12.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .~3BNC117: Intravenous Infusion of 3BNC117~Romidepsin: Intravenous Infusion of Romidepsin | 4 | 11 | OG000 |
| Group 2 | Group B | Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .~Romidepsin: Intravenous Infusion of Romidepsin | 4 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Plasma HIV-1 RNA
- Description
As measured by a routine clinical assay (Cobas Taqman; detection limit 20 copies/mL), a transcription mediated amplification (TMA)-based assay (detection limit 12 copies/ml) and/or a single copy assay (detection limit 1-2 copies/mL)
- Time frame
- 48 weeks
- Population
- Participants with detectable plasma HIV-1RNA during the treatment cycles measure by commercial assays.
Source ClinicalTrials.gov
Trial
- Title
- Romidepsin Plus 3BNC117 Phase 2a Study
- NCT number
- NCT02850016
- Phases
- PHASE2
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- 3BNC117, Romidepsin
- Lead sponsor
- Rockefeller University
- Results first posted
- 2022-07-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02850016?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02850016-2f45fca2